Effect of sirolimus on infection incidence in liver transplant recipients

Liver Transplantation

Volumn 10, Issue 2, 2004, Pages 193-198

  Fisher, Adrian ^a   Seguel, Joseph M ^a   de la Torre, Andrew N ^a   Wilson, Dorian ^a   Merchant, Anand ^a   Arora, Rakesh K ^a   Koneru, Baburao ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BASILIXIMAB; CALCINEURIN INHIBITOR; CEPHALOSPORIN; CORTICOSTEROID; COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PENICILLIN G; RAPAMYCIN; SULTAMICILLIN; TACROLIMUS; VANCOMYCIN;

ACUTE GRAFT REJECTION; ADULT; ALLERGY; ARTERY THROMBOSIS; ARTICLE; CANDIDA ALBICANS; CHRONIC GRAFT REJECTION; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DEMOGRAPHY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GRAFT SURVIVAL; HEPATIC ARTERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY DYSFUNCTION; LENGTH OF STAY; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PERIOPERATIVE PERIOD; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; SEPSIS; STATISTICAL ANALYSIS; WOUND HEALING;

ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFECTION; LENGTH OF STAY; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 1242329783     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20072     Document Type: Article

References (16)

1. Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001;7:1181-1193.
2. Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000;57:437-448
3. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995;17:660-665.
4. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000;69:1252-1260.
5. Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998;66:1040-1046.
6. Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 2000;70:690-694.
7. Watson CJE, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999;67:505-509.
8. Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001;7:343-351.
9. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999;67:1036-1042.
10. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. Lancet 2000;356:194-202.
11. Kneteman NM, Meeberg G, Bonar S, et al. Sirolimus (SRL) immunosuppression for liver transplantation in the presence of malignancy [Abstract]. Presented at European Society for Organ Transplantation, 9th Congress, 1999; Oslo, Norway.
12. McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001;7:701-708.
13. Guilbeau J. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002;36:1391-1395.
14. Wiesner, R for the Rapamune Liver Transplant Study Group. The safety and efficacy of sirolimus and low-dose tacrolimus vs. tacrolimus in de novo orthotopic liver transplant recipients: results from a pilot study [Abstract]. Hepatology 2002;36:208A.
15. Kneteman N, Bigam D, Al-Saghier M, et al. Liver transplantation with a steroid-free, low-toxicity immunosuppressive protocol [Abstract]. Am J of Transplantation 2002;2(Suppl 3):197.
16. Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery thrombosis or wound complications. Liver Transpl 2003;9:463-468.